.Competing passions.R.S., M.S., H.G. as well as A.A.R. are actually coordinators of the 1M1M project. H.G. as well as A.A.R. are panel of supervisors participants and R.S., M.S. and A.A.R. are actually members of the clinical advising board of N1C. A.A.R. makes known job by LUMC, which possesses licenses on exon-skipping technology, a number of which has actually been accredited to BioMarin as well as consequently sublicensed to Sarepta. As co-inventor of a few of these licenses, A.A.R. was actually allowed to a share of nobilities. A.A.R. even further discloses serving as impromptu consultant for PTC Therapies, Sarepta Therapeutics, Regenxbio, Dyne Therapies, Lilly, BioMarin Pharmaceuticals Inc., Eisai, Entrada, Takeda, Splicesense, Galapagos, Sapreme, Italfarmaco and Astra Zeneca. Over the last 5 years, A.A.R. likewise performed consulting with for Alpha Anomeric. A.A.R. additionally mentions membership of the scientific advisory boards of Eisai, Hybridize Therapeutics, Muteness Therapies, Sarepta Rehabs, Sapreme and Mitorx. Previously 5 years, A.A.R. was additionally a scientific advisory board member for ProQR. Remuneration for A.A.R. u00e2 s consulting and advising activities is paid out to LUMC. Previously 5 years, LUMC also got audio speaker honoraria coming from PTC Therapies, Alnylam Netherlands, Italfarmaco as well as Pfizer and cashing for deal research study from Sapreme, Eisai, Galapagos, Synaffix as well as Alpha Anomeric. Job funding is obtained coming from Sarepta Therapies as well as Entrada by means of unconstrained gives. H.G. possesses nothing at all to divulge in connection with the subjects dealt with within this manuscript. Previously 5 years, he has also obtained working as a consultant honoraria coming from UCB. M.S. acquired working as a consultant gratuity coming from Ionis, UCB, Prevail, Orphazyme, Biogen, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, Lilly and Solaxa before 5 years, all unrelated to the here and now manuscript. R.S. possesses absolutely nothing to divulge in connection with the subjects covered within this manuscript. She has obtained audio speaker and/or consultancy gratuity or financing additions from Abbvie, Bial, STADA and Everpharma before 5 years.